Guanylate cyclase-C (GC-C) is a multifunctional receptor encoded by the <i>GUCY2C</i> gene, representing an attractive target for therapy in several gastrointestinal diseases in humans.
Plecanatide (Trulance<sup>TM</sup>) is an oral guanylate cyclase-C agonist that is being developed by Synergy Pharmaceuticals for the treatment of gastrointestinal disorders, such as chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).